Mizied Falah
Directeur Technique/Scientifique/R&D chez VESSL Therapeutics Ltd.
Profil
Mizied Falah was the founder of GeneArrest Ltd., a company founded in 2009, where he held the title of Chief Technology Officer.
He is currently working at VESSL Therapeutics Ltd.
as the Director of Strategic Research & Development since 2013.
Dr. Falah obtained a doctorate degree from McMaster University in 1997 and completed undergraduate and graduate studies at The Hebrew University of Jerusalem.
Postes actifs de Mizied Falah
| Sociétés | Poste | Début |
|---|---|---|
VESSL Therapeutics Ltd.
 VESSL Therapeutics Ltd. Medical SpecialtiesHealth Technology VESSL Therapeutics Ltd. develops cell-based therapies for large patient populations. Its solutions include MultiGeneAngio fo Peripheral Artery Disease and MultiGeneGraft for end-stage renal disease. The company was founded in August 2000 by Moshe Y. Flugelman and Basil S. Lewis and is headquartered in Haifa, Israel. | Directeur Technique/Scientifique/R&D | - |
Anciens postes connus de Mizied Falah
| Sociétés | Poste | Fin |
|---|---|---|
GeneArrest Ltd.
 GeneArrest Ltd. Miscellaneous Commercial ServicesCommercial Services GeneArrest Ltd. develops drug discovery technology. Its antigene drug discovery platform is a route to capitalize on new insights in genomic information to make novel drugs. The company's technology is based on proprietary bioinformatics tools used to design selective and specific gene-silencing chemicals. GeneArrest was founded by Mizied Falah and Anwar Rayan in 2009 and is headquartered in Nazareth, Israel. | Fondateur | - |
Formation de Mizied Falah
| McMaster University | Doctorate Degree |
| The Hebrew University of Jerusalem | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
VESSL Therapeutics Ltd.
VESSL Therapeutics Ltd. Medical SpecialtiesHealth Technology VESSL Therapeutics Ltd. develops cell-based therapies for large patient populations. Its solutions include MultiGeneAngio fo Peripheral Artery Disease and MultiGeneGraft for end-stage renal disease. The company was founded in August 2000 by Moshe Y. Flugelman and Basil S. Lewis and is headquartered in Haifa, Israel. | Health Technology |
GeneArrest Ltd.
GeneArrest Ltd. Miscellaneous Commercial ServicesCommercial Services GeneArrest Ltd. develops drug discovery technology. Its antigene drug discovery platform is a route to capitalize on new insights in genomic information to make novel drugs. The company's technology is based on proprietary bioinformatics tools used to design selective and specific gene-silencing chemicals. GeneArrest was founded by Mizied Falah and Anwar Rayan in 2009 and is headquartered in Nazareth, Israel. | Commercial Services |
